Disease · OBA_VT0000183
blood pressure trait
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. blood pressure trait. Diseases, record OBA_VT0000183. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/OBA_VT0000183
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- blood pressure trait
- Open Targets ID
- OBA_VT0000183
- Other names
- blood pressure, pressure of blood
- Highest stage of its drugs
- Phase 3, for 2 of its 15 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs15
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| VALSARTAN | CHEMBL1069 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| AMLODIPINE | CHEMBL1491 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ASPIRIN | CHEMBL25 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CALCIUM | CHEMBL1200496 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CHOLECALCIFEROL | CHEMBL1042 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RAMIPRIL | CHEMBL1168 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SIMVASTATIN | CHEMBL1064 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MYCOPHENOLATE MOFETIL | CHEMBL1456 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DEXMEDETOMIDINE | CHEMBL778 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DROSPIRENONE | CHEMBL1509 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 15
See all 15 drugsTargets19
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| AGTR1 | Type-1 angiotensin II receptor | 2 | Type-1 angiotensin II receptor antagonist | Phase 3 | https://conductscience.org/library/genes/185 | Drugs and targets |
| ESR1 | Estrogen receptor | 2 | Estrogen receptor agonist; Estrogen receptor alpha agonist | Unknown | https://conductscience.org/library/genes/2099 | Drugs and targets |
| ACE | Angiotensin-converting enzyme | 1 | Angiotensin-converting enzyme inhibitor | Phase 2 | https://conductscience.org/library/genes/1636 | Drugs and targets |
| ADRA2A | Adrenergic receptor alpha-2 | 1 | Adrenergic receptor alpha-2 agonist | Unknown | https://conductscience.org/library/genes/150 | Drugs and targets |
| ADRA2B | Adrenergic receptor alpha-2 | 1 | Adrenergic receptor alpha-2 agonist | Unknown | https://conductscience.org/library/genes/151 | Drugs and targets |
| ADRA2C | Adrenergic receptor alpha-2 | 1 | Adrenergic receptor alpha-2 agonist | Unknown | https://conductscience.org/library/genes/152 | Drugs and targets |
| CACNA1C | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 3 | https://conductscience.org/library/genes/775 | Drugs and targets |
| CACNA1D | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 3 | https://conductscience.org/library/genes/776 | Drugs and targets |
| CACNA1F | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 3 | https://conductscience.org/library/genes/778 | Drugs and targets |
| CACNA1S | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 3 | https://conductscience.org/library/genes/779 | Drugs and targets |
1 to 10 of 19
See all 19 targetsTrials8
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01005290 | A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Blood Pressure | Phase 2 | 38 | 2012-07-26 | Hypertension | ASPIRIN, RAMIPRIL, SIMVASTATIN | Its record names the disease | ClinicalTrials.gov |
| NCT03070483 | Blood Pressure in Blacks and Calcium (BBC) and Vitamin D Study | Phase 2 | 5 | 2020-06-24 | Hypertension, Vitamin D Deficiency | CALCIUM, CHOLECALCIFEROL | Its record names the disease | ClinicalTrials.gov |
| NCT00350168 | Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Patients With Stage II Hypertension | Phase 3 | 647 | Hypertension | AMLODIPINE, VALSARTAN | Its record names the disease | ClinicalTrials.gov | |
| NCT07061093 | Prospective Evaluation on the Role Exerted by Hormonal Contraceptives on 24-h Blood Pressure. A Prospective Observational Study | 96 | Cardiovascular System Diseases (&Amp; [Cardiac]) | DROSPIRENONE, ESTETROL | Its record names the disease | ClinicalTrials.gov | ||
| NCT02432339 | Effects of an Immunosuppressant Mycophenolate Mofetil or MMF on the Urinary Sodium Excretion Response to Mental Stress | Phase 1/2 | 50 | Psychological Stress, Hypertension, Renal | MYCOPHENOLATE MOFETIL | Its record names the disease | ClinicalTrials.gov | |
| NCT00732966 | Ocsaar and CYP2C9 Ploymorphism, Is There a Connection Between Pharmacokinetics, Pharmacodynamics and Pharmacogenetics? | Not applicable | 30 | Hypertension | LOSARTAN, VALSARTAN | Its record names the disease | ClinicalTrials.gov | |
| NCT03076099 | Dexmedetomidine on Post-operative Blood Pressure in Bain Arteriovenous Malformation Embolization | Not applicable | 30 | Anesthesia | DEXMEDETOMIDINE | Its record names the disease | ClinicalTrials.gov | |
| NCT01488383 | Effect of Stevioside in Postpandrial Glucose in Healthy Adults | Not applicable | 0 | Hyperglycemia, Hypertension | SACCHARIN, STEVIOSIDE | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials1
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial |
|---|---|---|---|---|
| Combination Pill vs Ramipril: serious adverse events | 0 of 29 | 0 of 31 | 60 | NCT01005290 |
Source Trial comparisons
Papers from its trials1
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it |
|---|---|---|
| 20409909 | RESULT | 1 |
Source PubMed
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/OBA_VT0000183
GET https://conductscience.org/api/diseases/v1/OBA_VT0000183/drugs